Late-demographic dividend vs Latvia: Immunization, HepB3
Late-demographic dividend
94.0%
in 2024
Latvia
99.0%
in 2024
Late-demographic dividend rank
3rd
Latvia rank
1st
Immunization, HepB3 over time
- Late-demographic dividend
- Latvia
How they compare
Latvia currently reports 99.0% against 94.0% in Late-demographic dividend, a difference of 5.0%.
That makes Latvia's figure about 1.1 times Late-demographic dividend's.
The two have swapped places 3 times across 28 shared years of data; in 1997 it was Late-demographic dividend ahead.
Late-demographic dividend ranks 3rd and Latvia ranks 1st of 47 groups.
Across the 4 decades both report, Late-demographic dividend averaged higher in 1 and Latvia in 3.
Head to head by decade
| Decade | Late-demographic dividend | Latvia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 15.8% | 36.3% | 20.5% | Latvia |
| 2000s | 82.3% | 95.4% | 13.1% | Latvia |
| 2010s | 96.7% | 94.1% | 2.6% | Late-demographic dividend |
| 2020s | 93.5% | 96.8% | 3.3% | Latvia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hepb3, Late-demographic dividend or Latvia?
- Latvia, at 99.0% against 94.0% in Late-demographic dividend as of 2024.
- What is the difference in immunization, hepb3 between Late-demographic dividend and Latvia?
- 5.0%, with Latvia ahead.
- How many years of comparable data are there for Late-demographic dividend and Latvia?
- 28 years are reported by both, from 1997 to 2024.
- How do Late-demographic dividend and Latvia rank globally for immunization, hepb3?
- Late-demographic dividend ranks 3rd and Latvia ranks 1st of 47 groups.
- Where does this data come from?
- World Health Organization (WHO), published as Immunization, HepB3 (% of one-year-old children). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization rate, hepatitis B is the percentage of children ages 12-23 months who received hepatitis B vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized after three doses.